Xpert® MRSA
1 / 2Pages

Xpert MRSA Loyola University Medical Center is an example of how active MRSA surveillance testing (first with the ICU patient population and then expanded to all patients), coupled with appropriate infection control practices, can successfully reduce MRSA infection rates by 67%. Total hands-on time: <1 Minute Introduction of ICU MRSA Screening (all patients admitted to ICU) INFECTIONS PER 1000 PATIENT DAYS Introduction of Universal MRSA Screening Insert swab into Sample Reagent vial and break LOYOLA UNIVERSITY MEDICAL CENTER NOSOCOMIAL MRSA INFECTION RATES4 Vortex and dispense Sample into Specimen Port Insert Cartridge and start assay Pre-surveillance rate (baseline): 0.5294 (all patients admitted to hospital) Universal surveillance rate: A study done at Centennial Medical Center in Nashville, TN compared the performance and turn-around times of samples of their ICU patients collected on admission. Samples were tested with BD CHROMAgar™ MRSA and Xpert® MRSA in the lab and results reported. Centennial was able to provide test results over 28 hours sooner using Xpert MRSA. TURN-AROUND TIMES OF POSITIVE RESULTS CALLED TO ICU5 Mean Turn Around Time (Hours) Xpert MRSA Test - Positive Result Cultures - Positive Results “[Using culture] would equate to an additional 44 HAI transmissions… which would indicate that the use of Xpert MRSA could save up to 11 MRSA infections…”5 References: 1. Annual epidemiological report on communicable diseases in Europe 2010. 2. Klein, E., Smith, D, Laxminarayan, R., ”Hospitalizations and deaths causted by Methicillin-resistant Staphylococcus aureus, United States, 1999-2005,” Emerging Infectious Diseases, 2007; 13; 1840-1846 3. Kuenhart, MJ, et al, “Methicillin-resistant Staphylococcus aureus-related hospitalizations, United States,” Emerging Infectious Disease 2005: 11:868-872 4. Parada, JP et al. Universal Inpatient Screening with Rapid PCR-Based Technology Reduces Nosocomial Methicillin Resistant Staphylococcus aureus (MRSA) Rates: May 2007 to September 2008. Poster presented at APIC. June 2009. 5. Lassiter, S et al. Rapid Detection of Methicillin-Resistant Staphylococcus aureus using the Cepheid GeneXpert® Dx System and the Xpert® MRSA Test. Poster presented at ASM 2008. 6. Nahimana I, et al. Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROMagar MRSA) and ORSAB for surveillance cultures of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12: 1168-1174. Redefining Active MRSA Management Healthcare’s #1 choice for on-demand MRSA testing. The molecular revolution is here. CORPORATE HEADQUARTERS EUROPEAN HEADQUARTERS DIRECT SALES OFFICES 904 Caribbean Drive Sunnyvale, CA 94089 USA Vira Solelh 81470 Maurens-Scopont, France TOLL FREE A better way. THE PURCHASE OF THIS PRODUCT ALLOWS THE PURCHASER TO USE IT FOR THE PERFORMANCE OF DIAGNOSTIC SERVICES FOR HUMAN IN VITRO DIAGNOSTICS. NO GENERAL PATENT OR OTHER LICENSE OF ANY KIND OTHER THAN THIS SPECIFIC RIGHT OF USE FROM PURCHASE IS GRANTED HEREBY. NO OTHER RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR ESTOPPEL TO ANY OTHER PATENTS. FUTHERMORE, NO RIGHTS FOR RESALE ARE CONFERRED WITH THE PURCHASE OF THIS PRODUCT. In Vitro Diagnostic Medical Device 0002-06

“The GeneXpert System has taken the TAT of results from 2-3 days down to a few hours. Now we do not have to presumptively isolate patients. This has helped to reduce nursing labor, improve bed management and reduce isolation costs in the ICU.” Mary Jane Larmon, RN, BSN, MBA ICU Nurse Manager, Sharon Regional Health System The Xpert MRSA advantage: Actionable information sooner ® Performance characteristics of Xpert® MRSA were determined in a multi-site prospective investigation study at seven institutions by comparing Xpert MRSA with enriched culture, the most sensitive culture method. •...